LERCHEN, HANS-GEORG,兰钦 汉斯乔治,蘭欽 漢斯喬治,HAMMER, STEFANIE,汉默 史黛芬妮,漢默 史黛芬妮,HARRENGA, AXEL,哈伦加 阿克塞尔,哈倫加 阿克塞爾,KOPITZ, CHARLOTTE CHRISTINE,科普兹 夏洛特,科普茲 夏洛特,NISING, CARL FRIEDRICH,尼辛 卡罗,尼辛 卡羅,SOMMER, ANETTE,索莫尔
申请号：
TW101147076
公开号：
TW201339175A
申请日:
2012.12.13
申请国别(地区):
TW
年份:
2013
代理人:
摘要：
The present application relates to new binder-drug conjugates (ADCs)的 N,N-dialkylauristatins that are directed against the target FGFR2, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.本發明係關於針對目標FGFR2之新穎的N,N-二烷基奧瑞他汀(dialkylauristatin)之黏合劑-藥物接合體(ADC)、這些ADC之活性代謝物、製備這些ADC之方法、這些ADC用於治療及/或預防疾病之用途,以及這些ADC用於製造醫藥品供治療及/或預防疾病,更特別是,過度增生性及/或血管新生性疾病,例如癌症之用途。此等治療可以單一治療或另外與其他醫藥品或其他治療方法組合來施行。
